Soleno Therapeutics (SLNO) Property, Plant & Equipment (Net) (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.19% |
| Dec 31, 2025 | 23.33% |
| Sep 30, 2025 | -9.64% |
| Jun 30, 2025 | -4.05% |
| Mar 31, 2025 | -6.99% |
| Dec 31, 2024 | -5.10% |
| Sep 30, 2024 | 931.58% |
| Jun 30, 2024 | -29.63% |
| Mar 31, 2024 | 125.00% |
| Dec 31, 2023 | -20.00% |
| Sep 30, 2023 | -21.05% |
| Jun 30, 2023 | -13.64% |
| Mar 31, 2023 | -15.38% |
| Dec 31, 2022 | 13.04% |
| Sep 30, 2022 | -17.86% |
| Jun 30, 2022 | 3.70% |
| Mar 31, 2022 | -18.18% |
| Dec 31, 2021 | 26.92% |
| Sep 30, 2021 | -3.70% |
| Jun 30, 2021 | 35.00% |
| Mar 31, 2021 | 5.26% |
| Dec 31, 2020 | -5.00% |
| Sep 30, 2020 | 17.65% |
| Jun 30, 2020 | -10.53% |
| Mar 31, 2020 | -13.64% |
| Dec 31, 2019 | -52.17% |
| Sep 30, 2019 | 109.09% |
| Jun 30, 2019 | 15.79% |
| Mar 31, 2019 | 58.33% |
| Dec 31, 2018 | -14.29% |
| Sep 30, 2018 | 7.69% |
| Jun 30, 2018 | -23.53% |
| Mar 31, 2018 | -26.09% |
| Dec 31, 2017 | -58.18% |
| Sep 30, 2017 | 3.77% |
| Jun 30, 2017 | -43.01% |
| Mar 31, 2017 | 121.32% |
| Dec 31, 2016 | -63.78% |
| Sep 30, 2016 | -1.69% |
| Jun 30, 2016 | -2.48% |
| Mar 31, 2016 | 41.12% |
| Dec 31, 2015 | -12.51% |
| Sep 30, 2015 | 127.91% |
| Jun 30, 2015 | -2.27% |
| Mar 31, 2015 | -23.62% |
| Dec 31, 2014 | 60.02% |